Lotus Pharmaceutical Co Ltd
TWSE:1795
Lotus Pharmaceutical Co Ltd
Net Income (Common)
Lotus Pharmaceutical Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Net Income (Common)
NT$4.3B
|
CAGR 3-Years
43%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Net Income (Common)
NT$1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Net Income (Common)
NT$392.9m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
16%
|
CAGR 10-Years
5%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Net Income (Common)
NT$399.4m
|
CAGR 3-Years
26%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-6%
|
|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Net Income (Common)
NT$484.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-4%
|
CAGR 10-Years
7%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Net Income (Common)
NT$847.6m
|
CAGR 3-Years
7%
|
CAGR 5-Years
18%
|
CAGR 10-Years
10%
|
|
Lotus Pharmaceutical Co Ltd
Glance View
Lotus Pharmaceutical Co., Ltd., nestled at the intersection of innovation and healthcare, has carved a niche in the competitive pharmaceuticals landscape. Founded in Taiwan, Lotus has evolved into a prominent player, with a strategic focus on the development, manufacturing, and distribution of high-barrier generic drugs and specialty pharmaceuticals. Its journey began as a local pharmaceutical manufacturer but rapidly expanded its horizons through well-timed acquisitions and partnerships. These strategic moves have not only broadened its portfolio but also fortified its foothold in various international markets. The company leverages cutting-edge research and development capabilities to produce cost-effective alternatives to branded medications, which require significant expertise to replicate due to complex manufacturing processes and stringent regulatory requirements. Lotus’s operations hinge on its ability to navigate the intricacies of pharmaceutical regulations and patent landscapes, enabling it to introduce generics as soon as original drug patents expire. This strategic agility allows the company to capture market share quickly and maximize its revenue potential. Lotus Commercializes its products primarily in Asia while also extending its reach to North America and Europe through a network of collaborations and partnerships. Its robust portfolio spans several therapeutic areas, including oncology, central nervous system disorders, and cardiovascular diseases, where the demand for affordable medications is acute. As a result, Lotus not only generates substantial revenue but also plays a pivotal role in enhancing healthcare accessibility and affordability across the globe.
See Also
What is Lotus Pharmaceutical Co Ltd's Net Income (Common)?
Net Income (Common)
4.3B
TWD
Based on the financial report for Sep 30, 2024, Lotus Pharmaceutical Co Ltd's Net Income (Common) amounts to 4.3B TWD.
What is Lotus Pharmaceutical Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
49%
Over the last year, the Net Income (Common) growth was 12%. The average annual Net Income (Common) growth rates for Lotus Pharmaceutical Co Ltd have been 43% over the past three years , 49% over the past five years .
You don't have any saved screeners yet